Company intelligence / Profile preview

Oncotelic Therapeutics, Inc.

Ownership: Public · OTLC
Employees: ~26
Development stage: Phase 2

Overview

Oncotelic has advanced its lead program OT‑101 through several phase II trials for both oncology and COVID‑19. OT‑101 demonstrated positive safety and efficacy data in a randomized phase II trial for COVID pneumonia. In oncology, it has shown single-agent activity in relapsed/refractory cancers. The company also holds rare pediatric disease designations for DIPG and continues to expand its pipeline into additional orphan oncology indications.

Therapeutic areas: OncologyInfectious Diseases
Modalities: RNA therapeutics (antisense oligonucleotides)Small molecules
Industry: Biotech

Drug pipeline

7 assets

trabedersen

6 more assets in the full pipeline.

Partnerships

Merck & Co., Inc. – supplies pembrolizumab for combination therapy trials with OT–101 in mesothelioma patients.Joint venture partners Dragon and GMP Bio co-own certain assets such as OT–101.

Financials

Market cap: $4.6M
Total revenue: $0
Enterprise value: $18.3M

Beyond the preview

Go deeper on Oncotelic Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncotelic Therapeutics, Inc..